CEL-SCI Co. (NYSEAMERICAN:CVM) was the target of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,733,548 shares, a decline of 1.4% from the October 15th total of 1,757,327 shares. Currently, 6.7% of the company’s shares are short sold. Based on an average daily trading volume, of 370,405 shares, the short-interest ratio is currently 4.7 days.
A hedge fund recently raised its stake in CEL-SCI stock. BlackRock Inc. boosted its position in CEL-SCI Co. (NYSEAMERICAN:CVM) by 370.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 603,914 shares of the company’s stock after buying an additional 475,600 shares during the period. BlackRock Inc. owned approximately 2.14% of CEL-SCI worth $2,446,000 at the end of the most recent quarter.
CVM stock opened at $2.83 on Friday. CEL-SCI has a 12-month low of $0.82 and a 12-month high of $4.44.
CEL-SCI (NYSEAMERICAN:CVM) last released its earnings results on Tuesday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $0.10 million for the quarter.
Separately, TheStreet lowered shares of CEL-SCI from a “c-” rating to a “d” rating in a report on Monday, August 6th.
ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/11/10/short-interest-in-cel-sci-co-cvm-drops-by-1-4.html.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts.
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.